EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY 4.0

Myopia progression following 0.01% atropine cessation in Australian children: Findings from the Western Australia – Atropine for the Treatment of Myopia ( WA‐ATOM ) study

Samantha Sze-Yee Lee iD, Vinay Kumar Nilagiri iD, Gareth Lingham iD, Magdalena Blaszkowska iD, Paul G Sanfilippo iD, Maria Franchina iD, Antony Clark iD, David A Mackey iD

Clinical & Experimental Ophthalmology · 2024-07 · 52 (5) · 507-515

DOI: 10.1111/ceo.14368 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Clinical & Experimental Ophthalmology, online erschienen am 23.02.2024. Verfasst von Samantha Sze-Yee Lee und 7 weiteren Autor:innen. Beteiligte Einrichtung: Centre for Ophthalmology and Visual Science (incorporating the Lions Eye Institute), University of Western Australia, Perth, Western Australia, Austr…. Hauptthemen laut MEDLINE: Atropine, Disease Progression, Ophthalmic Solutions, Mydriatics. Die Arbeit wurde bisher 23-mal zitiert (Crossref) und nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ophthalmic Research Institute of Australia, Raine Medical Research Foundation, Faculty of Medicine, Dentistry and Health Sciences, University of Western Australia.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

A rebound in myopia progression following cessation of atropine eyedrops has been reported, yet there is limited data on the effects of stopping 0.01% atropine compared to placebo control. This study tested the hypothesis that there is minimal rebound myopia progression after cessation of 0.01% atropine eyedrops, compared to a placebo.

Methods

Children with myopia ( n = 153) were randomised to receive 0.01% atropine eyedrops or a placebo (2:1 ratio) daily at bedtime during the 2‐year treatment phase of the study. In the third year (wash‐out phase), all participants ceased eyedrop instillation. Participants underwent an eye examination every 6 months, including measurements of spherical equivalent (SphE) after cycloplegia and axial length (AL). Changes in the SphE and AL during the wash‐out phase and throughout the 3 years of the study (treatment + wash‐out phase) were compared between the treatment and control groups.

Results

During the 1‐year wash‐out phase, SphE and AL progressed by −0.41D (95% CI = −0.33 to −0.22) and +0.20 mm (95% CI = −0.46 to −0.36) in the treatment group compared to −0.28D (95% CI = 0.11 to 0.16) and +0.13 mm (95% CI = 0.18 to 0.21) in the control group. Progression in the treatment group was significantly faster than in the control group ( p = 0.016 for SphE and

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AtropineDisease ProgressionOphthalmic SolutionsMydriaticsRefraction, OcularAxial Length, EyeHumansMaleFemaleChildDouble-Blind MethodMyopiaWestern AustraliaAdolescent

Stichwörter der Autor:innen

Australiaatropineaxial lengthmyopiamyopia control

Substanzen

AtropineOphthalmic SolutionsMydriatics

Autor:innen und Institutionen

  • Centre for Ophthalmology and Visual Science (incorporating the Lions Eye Institute), University of Western Australia, Perth, Western Australia, Australia.
  • Centre for Eye Research Ireland, Environmental, Sustainability and Health Institute, Technological University Dublin, Dublin, Ireland.
  • Centre for Eye Research Australia, University of Melbourne, Royal Victorian Eye and Ear Hospital, Melbourne, Victoria, Australia.
  • Perth Children's Hospital, Perth, Western Australia, Australia.
  • School of Medicine, Menzies Research Institute Tasmania, University of Tasmania, Hobart, Tasmania, Australia.

ORCID-Profile: Samantha Sze-Yee Lee, Vinay Kumar Nilagiri, Gareth Lingham, Magdalena Blaszkowska, Paul G Sanfilippo, Maria Franchina, Antony Clark, David A Mackey

Förderung

  • Ophthalmic Research Institute of Australia
  • Raine Medical Research Foundation
  • Faculty of Medicine, Dentistry and Health Sciences, University of Western Australia
  • Telethon Kids Institute
  • University of Western Australia
  • Telethon-Perth Children's Hospital Research Fund
  • Healy Medical Research Foundation
  • National Health and Medical Research Council

Zitieren

APA

Lee, S. S., Nilagiri, V. K., Lingham, G., Blaszkowska, M., Sanfilippo, P. G., Franchina, M., Clark, A., & Mackey, D. A. (2024). Myopia progression following 0.01% atropine cessation in Australian children: Findings from the Western Australia – Atropine for the Treatment of Myopia ( WA‐ATOM ) study. Clinical & Experimental Ophthalmology, 52(5), 507-515. https://doi.org/10.1111/ceo.14368

Vancouver

Lee SS, Nilagiri VK, Lingham G, Blaszkowska M, Sanfilippo PG, Franchina M, et al. Myopia progression following 0.01% atropine cessation in Australian children: Findings from the Western Australia – Atropine for the Treatment of Myopia ( WA‐ATOM ) study. Clinical & Experimental Ophthalmology. 2024;52(5):507-515. doi:10.1111/ceo.14368

BibTeX
@article{Lee2024,
  author = {Lee, Samantha Sze-Yee and Nilagiri, Vinay Kumar and Lingham, Gareth and Blaszkowska, Magdalena and Sanfilippo, Paul G and Franchina, Maria and Clark, Antony and Mackey, David A},
  title = {Myopia progression following 0.01% atropine cessation in Australian children: Findings from the Western Australia – Atropine for the Treatment of Myopia ( WA‐ATOM ) study},
  journal = {Clinical & Experimental Ophthalmology},
  year = {2024},
  volume = {52},
  number = {5},
  pages = {507--515},
  doi = {10.1111/ceo.14368}
}
Kostenlos starten →